Low incidence of oncogenic EGFR, HRAS, and KRAS mutations in seborrheic keratosis

American Journal of Dermatopathology

Volumn 36, Issue 8, 2014, Pages 635-642

  Georgieva, Ivelina A ^a,b   Mauerer, Andreas ^a   Groesser, Leopold ^a   Herschberger, Eva ^a   Aslanidis, Charalampos ^a   Dietmaier, Wolfgang ^a   Landthaler, Michael ^a   Hafner, Christian ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

EGFR; FGFR2; oncogenic mutation; PIK3R1; RAS; seborrheic keratosis

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; EXON; FEMALE; FIBROBLAST GROWTH FACTOR RECEPTOR 2 GENE; FIBROBLAST GROWTH FACTOR RECEPTOR 3 GENE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; INCIDENCE; MALE; ONCOGENE; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; PATHOGENESIS; PHOSPHATIDYLINOSITOL 3 KINASE GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEBORRHEIC KERATOSIS; VERY ELDERLY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PHENOTYPE;

EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; FGFR2 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR RECEPTOR 2; HRAS PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3R1 PROTEIN, HUMAN; PROTEIN P21; RAS PROTEIN; TUMOR MARKER;

ADULT; AGED; AGED, 80 AND OVER; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KERATOSIS, SEBORRHEIC; MALE; MIDDLE AGED; MUTATION; ONCOGENES; PHENOTYPE; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS P21(RAS); RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; TUMOR MARKERS, BIOLOGICAL;

EID: 84905109891     PISSN: 01931091     EISSN: 15330311     Source Type: Journal    
DOI: 10.1097/DAD.0b013e31828c0542     Document Type: Article

References (72)

1. Hafner C, Vogt T. Seborrheic keratosis. J Dtsch Dermatol Ges. 2008;6: 664-677.
2. Hafner C, Vogt T, Landthaler M, et al. Somatic FGFR3 and PIK3CA mutations are present in familial seborrhoeic keratoses. Br J Dermatol. 2008;159:214-217.
3. Rongioletti F, Corbella L, Rebora A. Multiple familial seborrheic keratoses. Dermatologica. 1988;176:43-45.
4. Hafner C, Toll A, Fernandez-Casado A, et al. Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumors. Proc Natl Acad Sci U S A. 2010;107:20780-20785.
5. Roymans D, Slegers H. Phosphatidylinositol 3-kinases in tumor progression. Eur J Biochem. 2001;268:487-498.
6. Hafner C, Lopez-Knowles E, Luis NM, et al. Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern. Proc Natl Acad Sci U S A. 2007;104:13450-13454.
7. Sjodahl G, Lauss M, Gudjonsson S, et al. A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1. PLoS One. 2011;6:e18583.
8. Philp AJ, Campbell IG, Leet C, et al. The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res. 2001;61:7426-7429.
9. Network CGAR. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455:1061-1068.
10. Zhang Y, Gorry MC, Post JC, et al. Genomic organization of the human fibroblast growth factor receptor 2 (FGFR2) gene and comparative analysis of the human FGFR gene family. Gene. 1999;230:69-79.
11. Belleudi F, Purpura V, Torrisi MR. The receptor tyrosine kinase FGFR2b/KGFR controls early differentiation of human keratinocytes. PLoS One. 2011;6:e24194.
12. Pollock PM, Gartside MG, Dejeza LC, et al. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene. 2007;26:7158-7162.
13. Dutt A, Salvesen HB, Chen TH, et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A. 2008;105: 8713-8717.
14. Marks JL, McLellan MD, Zakowski MF, et al. Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4. PLoS One. 2007;2:e426.
15. Jang JH, Shin KH, Park JG. Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res. 2001;61:3541-3543.
16. Gartside MG, Chen H, Ibrahimi OA, et al. Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma. Mol Cancer Res. 2009; 7:41-54.
17. de Ravel TJ, Taylor IB, Van Oostveldt AJ, et al. A further mutation of the FGFR2 tyrosine kinase domain in mild Crouzon syndrome. Eur J Hum Genet. 2005;13:503-505.
18. Rutland P, Pulleyn LJ, Reardon W, et al. Identical mutations in the FGFR2 gene cause both Pfeiffer and Crouzon syndrome phenotypes. Nat Genet. 1995;9:173-176.
19. Gorry MC, Preston RA, White GJ, et al. Crouzon syndrome: mutations in two spliceoforms of FGFR2 and a common point mutation shared with Jackson-Weiss syndrome. Hum Mol Genet. 1995;4:1387-1390.
20. Jabs EW, Li X, Scott AF, et al. Jackson-Weiss and Crouzon syndromes are allelic with mutations in fibroblast growth factor receptor 2. Nat Genet. 1994;8:275-279.
21. Park WJ, Meyers GA, Li X, et al. Novel FGFR2 mutations in Crouzon and Jackson-Weiss syndromes show allelic heterogeneity and phenotypic variability. Hum Mol Genet. 1995;4:1229-1233.
22. Meyers GA, Day D, Goldberg R, et al. FGFR2 exon IIIa and IIIc mutations in Crouzon, Jackson-Weiss, and Pfeiffer syndromes: evidence for missense changes, insertions, and a deletion due to alternative RNA splicing. Am J Hum Genet. 1996;58:491-498.
23. Wilkie AO, Slaney SF, Oldridge M, et al. Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome. Nat Genet. 1995;9:165-172.
24. Przylepa KA, Paznekas W, Zhang M, et al. Fibroblast growth factor receptor 2 mutations in Beare-Stevenson cutis gyrata syndrome. Nat Genet. 1996;13:492-494.
25. Passos-Bueno MR, Wilcox WR, Jabs EW, et al. Clinical spectrum of fibroblast growth factor receptor mutations. Hum Mutat. 1999;14: 115-125.
26. Kompier LC, Lurkin I, van der Aa MN, et al. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One. 2010;5:e13821.
27. Hafner C, Vogt T, Hartmann A. FGFR3 mutations in benign skin tumors. Cell Cycle. 2006;5:2723-2728.
28. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.
29. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet. 2003;33:19-20.
30. Dankort D, Curley DP, Cartlidge RA, et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet. 2009;41:544-552.
31. Michaloglou C, Vredeveld LC, Soengas MS, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature. 2005;436: 720-724.
32. Hida Y, Kubo Y, Arase S. Activation of fibroblast growth factor receptor 3 and oncogene-induced senescence in skin tumours. Br J Dermatol. 2009;160:1258-1263.
33. Woodman SE, Mills GB. Are oncogenes sufficient to cause human cancer? Proc Natl Acad Sci U S A. 2010;107:20599-20600.
34. Lazebnik Y. What are the hallmarks of cancer? Nat Rev Cancer. 2010; 10:232-233.
35. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-2516.
36. Hallermann C, Gunawan B, Bertsch HP. No chromosomal imbalances in seborrheic keratoses detectable by comparative genomic hybridization. J Invest Dermatol. 2004;123:1204-1205.
37. Naruke Y, Nakashima M, Suzuki K, et al. Alteration of p53-binding protein 1 expression during skin carcinogenesis: association with genomic instability. Cancer Sci. 2008;99:946-951.
38. Hafner C, Toll A, Real FX. HRAS mutation mosaicism causing urothelial cancer and epidermal nevus. N Engl J Med. 2011;365:1940-1942.
39. Teng YH, Tan WJ, Thike AA, et al. Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy. Breast Cancer Res. 2011;13:R35.
40. Tapia C, Savic S, Bihl M, et al. EGFR-mutations analyse beim nichtkleinzelligen lungenkarzinom. Erfahrungen aus der Routinediagnostik. Pathologe. 2009;30:384-392.
41. Kato Y, Peled N, Wynes MW, et al. Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations. J Thorac Oncol. 2010;5:1551-1558.
42. Wong AJ, Bigner SH, Bigner DD, et al. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci U S A. 1987;84: 6899-6903.
43. Lankiewicz S, Rother E, Zimmermann S, et al. Tumour-associated transcripts and EGFR deletion variants in colorectal cancer in primary tumour, metastases and circulating tumour cells. Cell Oncol. 2008;30: 463-471.
44. Peraldo-Neia C, Migliardi G,Mello-Grand M, et al. Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer. BMC Cancer. 2011;11:31.
45. Maihle NJ, Baron AT, Barrette BA, et al. EGF/ErbB receptor family in ovarian cancer. Cancer Treat Res. 2002;107:247-258.
46. Mauerer A, Herschberger E, Dietmaier W, et al. Low incidence of EGFR and HRAS mutations in cutaneous squamous cell carcinomas of a German cohort. Exp Dermatol. 2011;20:848-850.
47. Sordella R, Bell DW, Haber DA, et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004; 305:1163-1167.
48. Kumar A, Petri ET, Halmos B, et al. Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol. 2008;26:1742-1751.
49. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer. 2007;7:295-308.
50. Caldas C, Kern SE. K-ras mutation and pancreatic adenocarcinoma. Int J Pancreatol. 1995;18:1-6.
51. Chen HC, Chen HJ, Khan MA, et al. Genetic mutations of p53 and k-ras in gastric carcinoma patients from Hunan, China. Tumour Biol. 2011;32: 367-373.
52. Kim SW, Her KH, Jang JY, et al. K-ras oncogene mutation in cancer and precancerous lesions of the gallbladder. J Surg Oncol. 2000;75:246-251.
53. Krypuy M, Newnham GM, Thomas DM, et al. High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer. 2006;6:295.
54. Newell P, Toffanin S, Villanueva A, et al. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol. 2009;51:725-733.
55. Milasin J, Pujic N, Dedovic N, et al. H-ras gene mutations in salivary gland pleomorphic adenomas. Int J Oral Maxillofac Surg. 1993;22: 359-361.
56. Corominas M, Kamino H, Leon J, et al. Oncogene activation in human benign tumors of the skin (keratoacanthomas): is HRAS involved in differentiation as well as proliferation? Proc Natl Acad Sci U S A. 1989;86:6372-6376.
57. van Engen-van Grunsven AC, van Dijk MC, Ruiter DJ, et al. HRASmutated Spitz tumors: a subtype of Spitz tumors with distinct features. Am J Surg Pathol. 2010;34:1436-1441.
58. Da Forno PD, Pringle JH, Fletcher A, et al. BRAF, NRAS and HRAS mutations in spitzoid tumours and their possible pathogenetic significance. Br J Dermatol. 2009;161:364-372.
59. Hafner C, Toll A, Gantner S, et al. Keratinocytic epidermal nevi are associated with mosaic RAS mutations. J Med Genet. 2012;49:249-253.
60. Bourdeaut F, Herault A, Gentien D, et al. Mosaicism for oncogenic G12D KRAS mutation associated with epidermal nevus, polycystic kidneys and rhabdomyosarcoma. J Med Genet. 2010;47:859-862.
61. Groesser L, Herschberger E, Ruetten A, et al. Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome. Nat Genet. 2012;44:783-787. doi : 10.1038/ng.2316.
62. Daya-Grosjean L, Robert C, Drougard C, et al. High mutation frequency in ras genes of skin tumors isolated from DNA repair deficient xeroderma pigmentosum patients. Cancer Res. 1993;53:1625-1629.
63. Yamaguchi TP, Rossant J. Fibroblast growth factors in mammalian development. Curr Opin Genet Dev. 1995;5:485-491.
64. McKeehan WL, Wang F, Kan M. The heparan sulfate-fibroblast growth factor family: diversity of structure and function. Prog Nucleic Acid Res Mol Biol. 1998;59:135-176.
65. Cappellen D, De Oliveira C, Ricol D, et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet. 1999;23: 18-20.
66. Hafner C, Hartmann A, Vogt T. FGFR3 mutations in epidermal nevi and seborrheic keratoses: lessons from urothelium and skin. J Invest Dermatol. 2007;127:1572-1573.
67. Hafner C, van Oers JM, Vogt T, et al. Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. J Clin Invest. 2006;116: 2201-2207.
68. Logie A, Dunois-Larde C, Rosty C, et al. Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Hum Mol Genet. 2005;14:1153-1160.
69. Hafner C, Hartmann A, Real FX, et al. Spectrum of FGFR3 mutations in multiple intraindividual seborrheic keratoses. J Invest Dermatol. 2007; 127:1883-1885.
70. Hafner C, Di Martino E, Pitt E, et al. FGFR3 mutation affects cell growth, apoptosis and attachment in keratinocytes. Exp Cell Res. 2010; 316:2008-2016.
71. Hafner C, van Oers JM, Hartmann A, et al. High frequency of FGFR3 mutations in adenoid seborrheic keratoses. J Invest Dermatol. 2006;126: 2404-2407.
72. Hafner C, Hartmann A, van Oers JM, et al. FGFR3 mutations in seborrheic keratoses are already present in flat lesions and associated with age and localization. Mod Pathol. 2007;20:895-903.